HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, Y.-L. Articles by Yang, B.-C. Search for Related Content PubMed PubMed Citation Articles by Chen, Y.-L. Articles by Yang, B.-C. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH

Fas Ligand on Tumor Cells Mediates Inactivation of Neutrophils ¹

Yi-Ling Chen^*, Shun-Hua Chen, Jiu-Yao Wang and Bei-Chang Yang^2,

^* Institute of Basic Medical Sciences, and Departments of Microbiology and Immunology and Pediatrics, College of Medicine, National Cheng Kung University, Tainan, Taiwan, Republic of China

The expression of Fas ligand (FasL) on tumor cells (tumor FasL) has been implicated in their evasion of immune surveillance. In this study, we investigated the cellular mechanism for FasL-associated immune escape using melanoma B16F10-derived cells as a model. Transfectants carrying FasL-specific ribozymes expressed low levels of FasL (FasL^low tumor cells) as compared with those carrying enhanced green fluorescent protein-N1 plasmids (FasL^high tumor cells). When injected s.c. into C57BL/6 mice, FasL^low tumor cells grew more slowly than did FasL^high melanoma cells. FasL^high tumor cells showed more intensive neutrophilic infiltration accompanied by multiple necrotizing areas than did FasL^low tumor cells. The average size of FasL^low tumors, but not of FasL^high tumors, was significantly enhanced in mice depleted of neutrophils. Consistently, a local injection of LPS to recruit/activate neutrophils significantly delayed tumor formation by FasL^low tumor cells, and slightly retarded that of FasL^high tumor cells in both C57BL/6 and nonobese diabetic/SCID mice. Neutrophils killed FasL^low melanoma cells more effectively than FasL^high melanoma cells in vitro. The resistance of FasL^high melanoma cells to being killed by neutrophils was correlated with impaired neutrophil activation, as demonstrated by reductions in gelatinase B secretion, reactive oxygen species production, and the surface expression of CD11b and the transcription of FasL. Local transfer of casein-enriched or PMA-treated neutrophils delayed tumor formation by melanoma cells. Taken together, inactivation of neutrophils by tumor FasL is an important mechanism by which tumor cells escape immune attack.

This article has been cited by other articles:

				M. De Cesare, C. Calcaterra, G. Pratesi, L. Gatti, F. Zunino, S. Menard, and A. Balsari Eradication of Ovarian Tumor Xenografts by Locoregional Administration of Targeted Immunotherapy Clin. Cancer Res., September 1, 2008; 14(17): 5512 - 5518. [Abstract] [Full Text] [PDF]

				A. Chen, S. Liu, D. Park, Y. Kang, and G. Zheng Depleting Intratumoral CD4+CD25+ Regulatory T Cells via FasL Protein Transfer Enhances the Therapeutic Efficacy of Adoptive T Cell Transfer Cancer Res., February 1, 2007; 67(3): 1291 - 1298. [Abstract] [Full Text] [PDF]

				J. M. Challacombe, A. Suhrbier, P. G. Parsons, B. Jones, P. Hampson, D. Kavanagh, G. E. Rainger, M. Morris, J. M. Lord, T. T. T. Le, et al. Neutrophils Are a Key Component of the Antitumor Efficacy of Topical Chemotherapy with Ingenol-3-Angelate J. Immunol., December 1, 2006; 177(11): 8123 - 8132. [Abstract] [Full Text] [PDF]

				O. Bohana-Kashtan and C. I. Civin Profiling Tumor Counterattack: Do Fas Ligand-Containing Microvesicles Reduce Anticancer Immunity? Clin. Cancer Res., February 1, 2005; 11(3): 968 - 970. [Full Text] [PDF]